Abstract
Background BNP (brain natriuretic peptide) or NT-proBNP (N-terminal proBNP) is the only blood biomarker in the established risk calculators for pulmonary arterial hypertension (PAH). New plasma biomarkers of systemic origin may improve the risk assessment in PAH.
Methods We utilized a robust mass spectrometry-based method to identify prognostic plasma IgG N-glycome traits in PAH patients from two national referral centers in China (Beijing [discovery] cohort, n = 273; Shanghai cohort [validation], n = 349). Then the candidate IgG N-glycan traits were evaluated in combined cohorts adjusted for potential confounders and subgroup analyses. At last, the candidate IgG N-glycan traits were further evaluated against the established prognostic risk equation (three-strata model from the SPAHR and COMPERA analyses) for PAH. The primary endpoint was all-cause mortality.
Results IgG Fucosylation was found to predict survival independent of age and sex in the discovery cohort (HR: 0.377, 95% CI: 0.168-0.845, P = 0.018) with confirmation in the validation cohort (HR: 0.264, 95% CI: 0.445-0.751, P = 0.005). IgG Fucosylation remained a robust predictor of mortality in PAH patients in the combined cohorts adjusting for potential confounders and in subgroup analyses based on sex and treatment strategies. Moreover, the addition of the IgG Fucosylation to the established three-strata model significantly improved the predictive accuracy from AUC of 0.67 to AUC of 0.70 (P = 0.043) and IgG Fucosylation was useful in further stratifying the intermediate risk PAH patients classified by the three-strata model into intermediate-low and intermediate-high risk subgroups.
Conclusions The plasma IgG Fucosylation informs prognosis independent of the existing clinical assessments in PAH and may be useful in the clinical management of patients with PAH.
Clinical Perspective What is new?
The plasma IgG Fucosylation, which is in different pathophysiological pathways from other established risk factors of pulmonary arterial hypertension (PAH), can inform prognosis independent of the existing clinical assessments in patients with PAH.
The addition of the IgG Fucosylation to the established three-strata model for PAH prognosis significantly improved the predictive accuracy.
IgG Fucosylation was useful in further stratifying the intermediate risk PAH patients classified by the three-strata model into intermediate-high and intermediate-low risk subgroups.
What are the clinical implications?
Plasma IgG N-glycan biomarkers may provide a refined risk stratification in PAH used in combination with the established risk factors.
IgG Fucosylation involved in inflammatory pathways may not only be a promising prognostic biomarker but also a potential novel therapeutic target, distinct from existing targets, for patients with PAH.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Key Research and Development Program of China (2022YFC2703902 and 2022YFC2703901), the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-018), National Natural Science Foundation of China (82241020 and 32371506), Natural Science Foundation of Shanghai (22ZR1452400), Pujiang Talent Program (22PJD064), and National High-Level Hospital Clinical Research Funding (2022-PUMCH-B-099 and 2022-PUMCH-A-200).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Shanghai Pulmonary Hospital and FuWai Hospital gave ethical approval for this work. Written informed consent was obtained from all patients. This study complied with the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
